⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 3, 2008Genetic Vaccines and TherapyOpen Access

Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats

View Full Paper

Ask AI

Bookmark

Share

Abstract

Our results demonstrate that AAV8 is a robust vector for delivering therapeutic genes into rat liver following intravascular injection.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Graham et al. (2008) studied this question.

synapsesocial.com/papers/69dca26d0de68e8319e5327c https://doi.org/10.1186/1479-0556-6-9

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Limited Number of Transducible Hepatocytes Restricts a Wide-Range Linear Vector Dose Response in Recombinant Adeno-Associated Virus-Mediated Liver TransductionOriginal Research · 2002 · 97 citations
2Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectorsOriginal Research · 2004 · 358 citations
3Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liverOriginal Research · 2005 · 429 citations
4Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapyOriginal Research · 2005 · 171 citations
5Sustained correction of bleeding disorder in hemophilia B mice by gene therapyOriginal Research · 1999 · 224 citations